C12Y101/0104

Methods for efficient production of polyunsaturated fatty acids (PUFA) in Rhodosporidium and Rhodotorula species

The present invention relates to the field of fungal biotechnology, more particularly to genetic engineering methods for the production of polyunsaturated fatty acids (PUFA) in fungal hosts selected from Rhodosporidium and Rhodotorula genera. The present invention further relates to a modified fungal host cell having reduced native aldehyde dehydrogenase (ALD 1) enzyme activity, and methods for producing omega-3 and omega-6 fatty acids and triacylglycerides, by growing said fungal host cell under suitable conditions.

METHODS FOR EFFICIENT PRODUCTION OF POLYUNSATURATED FATTY ACIDS(PUFA) IN RHODOSPORIDIUM AND RHODOTORULA SPECIES

The present invention relates to the field of fungal biotechnology, more particularly to genetic engineering methods for the production of polyunsaturated fatty acids (PUFA) in fungal hosts selected from Rhodosporidium and Rhodotorula genera. The present invention further relates to a modified fungal host cell having reduced native aldehyde dehydrogenase (ALD 1) enzyme activity, and methods for producing omega-3 and omega-6 fatty acids and triacylglycerides, by growing said fungal host cell under suitable conditions.

NOVEL GENES ENCODING INSECTICIDAL PROTEINS
20170107534 · 2017-04-20 ·

The present invention relates to novel gene sequences encoding insecticidal proteins produced by Bacillus thuringiensis strains. Particularly, new chimeric genes encoding a CryIC, CryIB or CryID protein are provided which are useful to protect plants from insect damage. Also included herein are plant cells or plants comprising such genes and methods of making or using them, as well as plant cells or plants comprising one of such chimeric gene and at least one other such chimeric genes.

Pharmaceutical Composition for Treating or Preventing Disease Caused by Reduction or Deficiency in tm5U Modification
20250242051 · 2025-07-31 ·

The present invention provides a pharmaceutical composition for the treatment or prevention of a disease(s) caused by reduction or deficiency in 5-taurinomethyluridine (m.sup.5U) modification of mitochondrial tRNA, the composition comprising mitochondrial tRNA translation optimization 1 (MTO1) or nucleic acid encoding MTO1, wherein MTO1 is administered to a patient in an excess amount, or MTO1 is overexpressed in a patient to whom the nucleic acid has been administered.

L-GLUTAMIC ACID-PRODUCING MUTANT MICROORGANISM OF GENUS CORYNEBACTERIUM, AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAME

The present invention relates to a Corynebacterium sp. mutant microorganism producing L-glutamic acid and a method of producing L-glutamic acid using the same, and more specifically, to a novel NADP-dependent malic enzyme variant involved in the L-glutamic acid biosynthetic pathway, a polynucleotide, and a transformant, as well as a method of producing L-glutamic acid using the same. The NADP-dependent malic enzyme variant according to the present invention is obtained by substituting one or more amino acids in the amino acid sequence constituting NADP-dependent malic enzyme to change the enzymatic activity of the NADP-dependent malic enzyme, and a recombinant microorganism comprising the NADP-dependent malic enzyme variant is capable of efficiently producing L-glutamic acid.